PMID: 6981814Aug 1, 1982Paper

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

Proceedings of the National Academy of Sciences of the United States of America
A Van Pel, T Boon

Abstract

The nonimmunogenic thymic leukemia TH, obtained in mouse strain CBA/Ht, was adapted to culture. By in vitro treatment of a clonal TH cell line with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine, stable variant cell clones (tum-) were obtained that elicited a rejection response in syngeneic mice. Mice that had rejected a tum- variant were partially protected against a challenge with the original tumor. When spleen cells of these animals were restimulated in vitro, cytolytic T cells were obtained that were directed against an antigen present on the original tumor. The existence of these cytolytic effectors was confirmed by clonal analysis of the cytolytic response. No immune protection against TH was observed in mice that had been immunized with irradiated cells of the original TH tumor. These results confirm that tum- variants can elicit a syngeneic rejection response against tumors that are apparently devoid of transplantation immunogenicity. The experimental conditions and the results make it likely but not certain that the tumor-associated antigen detected on leukemia TH was present on the primary tumor.

References

Jan 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·T Boon, O Kellermann
Oct 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·A Van PelT Boon
Aug 1, 1970·Proceedings of the National Academy of Sciences of the United States of America·E BonmassarA Goldin
Jan 1, 1980·Immunological Reviews·H R MacDonaldK T Brunner
Nov 1, 1980·The Journal of Experimental Medicine·C UyttenhoveT Boon
Jan 1, 1981·Immunological Reviews·S Gillis, J Watson

❮ Previous
Next ❯

Citations

Jan 1, 1987·Cancer Metastasis Reviews·P PuccettiM C Fioretti
Jan 1, 1996·Springer Seminars in Immunopathology·H Chong, R G Vile
Jan 1, 1990·Cancer Immunology, Immunotherapy : CII·M KohlerR M Zinkernagel
Oct 1, 1992·Current Opinion in Immunology·D Pardoll
Sep 21, 2000·Immunology Letters·L EisenbachK El-Shami
Sep 21, 2000·Immunology Letters·E P Cohen
Apr 5, 2001·Trends in Molecular Medicine·E P Cohen
Nov 26, 2002·Immunological Reviews·Pierre G CoulieThierry Boon
Jan 21, 2006·Nature Reviews. Drug Discovery·David SchramaJürgen C Becker
Jul 31, 2010·Proceedings of the National Academy of Sciences of the United States of America·Padmanee Sharma
May 1, 1984·The Journal of Experimental Medicine·P FrostR S Kerbel
Aug 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher G TwittyBernard A Fox
Apr 27, 2000·American Journal of Respiratory Cell and Molecular Biology·S M DubinettS Sharma
Dec 15, 1996·The Journal of Clinical Investigation·J C BeckerR A Reisfeld
Mar 23, 2011·Future Oncology·Gabriel De LeonJohn Sampson
Feb 1, 2007·Frontiers of Medicine in China·Qingwen Xu, Weifeng Chen
Feb 11, 2014·Vaccine·Marieke F FransenCornelis J M Melief
Feb 4, 2014·Cancer Immunology, Immunotherapy : CII·Serena ChangHolden T Maecker
Aug 23, 2007·Digestive Diseases and Sciences·Maurizio Chiriva-InternatiEldo E Frezza
Apr 1, 2011·Expert Opinion on Biological Therapy·Bryan D ChoiJohn H Sampson
Dec 1, 2001·Expert Opinion on Biological Therapy·M MarchandP G Coulie
Jun 14, 2008·Expert Opinion on Biological Therapy·Vincent G Brichard, Diane Lejeune
Aug 4, 2009·Expert Opinion on Biological Therapy·Thomas Newsom-DavisMark Bower
Aug 13, 2011·Clinical Lung Cancer·David P Carbone, Enriqueta Felip
Aug 4, 2005·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·A McKechnieO Eremin
May 21, 2009·Experimental and Molecular Pathology·Rich-Henry SchabowskyHaval Shirwan
Jan 19, 2006·The Journal of Investigative Dermatology·Mads Hald AndersenJürgen C Becker
Sep 12, 2009·Brain Pathology·Bryan D ChoiJohn H Sampson
Nov 1, 1983·European Journal of Cancer & Clinical Oncology·M MarchandT Boon
May 1, 1984·Parasite Immunology·M Marchand, T Boon
Apr 12, 2003·Neuroimaging Clinics of North America·Peter E Fecci, John H Sampson
Jun 28, 2012·Oncoimmunology·Manuela IezziFederica Cavallo
Oct 8, 1999·Immunity·E Gilboa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.